capsule (or pill) developed by Cadila Pharmaceuticals Ltd.India. It's a miracle combination of Atenolol (50 mg), Thiazide (12·5 mg), Ramipril (5 mg), Simvastatin (20 mg) and Aspirin (100 mg) for primary prevention of cardiovascular events and stroke. The Indian Polycap study data was published in Lancet and presentation in the ACC 09 by Dr. Salim Yusuf of Mc Master University, Canada and Dr. Prem Pais of St. John’s Medical College, Bangalore on behalf of the Polycap investigators. “This study was entirely funded by Cadila Pharmaceuticals as contribution towards our goal of reducing the global burden of disease” said Cadila Pharmaceuticals chairman Shri I.A.Modi.
No comments:
Post a Comment